Letermovir

Samuel L. Aitken; Rob Saunders; Roy F. Chemaly; Gerhard Ehninger

doi:10.1201/9781315152110

Letermovir

Samuel L. Aitken, Rob Saunders, Roy F. Chemaly, Gerhard Ehninger

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Letermovir is the first representative of the nonnucleoside 3,4 dihydro-quinazoline class of human cytomegalovirus (HCMV) viral terminase complex inhibitors (Verghese and Schleiss, 2013). Originally developed by Bayer AG (Wuppertal, Germany), with further preclinical and clinical development through phase II by AiCuris GmbH & Co. KG (Wuppertal, Germany), letermovir is now under development by Merck & Co. (Kenilworth, NJ, USA). Letermovir is now in phase III development for the prevention of HCMV infection in allogeneic hematopoietic cell transplant (HCT) recipients (clinical trials NCT02137772). Owing to its development history, letermovir is variously known as BAY 73-6327, AIC246, and MK-8228. The chemical name of letermovir is 2-((4S)-8-fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)- 3-(2-methoxy-5)-trifluoromethyl)phenyl)-4H-quinazolin- 4-yl)acetic acid (PubChem Open Chemistry Database, 2016), the molecular formula is C₂₉H₂₈F₄N₄ O₄, and its molecular weight is 572.55 g/mol. The chemical structure is shown in Figure 220.1.

Original language	English (US)
Title of host publication	Kucers the Use of Antibiotics
Subtitle of host publication	A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
Publisher	CRC Press
Pages	3619-3626
Number of pages	8
ISBN (Electronic)	9781498747967
ISBN (Print)	9781498747950
DOIs	https://doi.org/10.1201/9781315152110
State	Published - Jan 1 2017
Externally published	Yes

ASJC Scopus subject areas

General Medicine
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1201/9781315152110

Cite this

@inbook{040b5a525309428b8f3b7e994eb5ca26,

title = "Letermovir",

abstract = "Letermovir is the first representative of the nonnucleoside 3,4 dihydro-quinazoline class of human cytomegalovirus (HCMV) viral terminase complex inhibitors (Verghese and Schleiss, 2013). Originally developed by Bayer AG (Wuppertal, Germany), with further preclinical and clinical development through phase II by AiCuris GmbH & Co. KG (Wuppertal, Germany), letermovir is now under development by Merck & Co. (Kenilworth, NJ, USA). Letermovir is now in phase III development for the prevention of HCMV infection in allogeneic hematopoietic cell transplant (HCT) recipients (clinical trials NCT02137772). Owing to its development history, letermovir is variously known as BAY 73-6327, AIC246, and MK-8228. The chemical name of letermovir is 2-((4S)-8-fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)- 3-(2-methoxy-5)-trifluoromethyl)phenyl)-4H-quinazolin- 4-yl)acetic acid (PubChem Open Chemistry Database, 2016), the molecular formula is C29H28F4N4 O4, and its molecular weight is 572.55 g/mol. The chemical structure is shown in Figure 220.1.",

author = "Aitken, {Samuel L.} and Rob Saunders and Chemaly, {Roy F.} and Gerhard Ehninger",

note = "Publisher Copyright: {\textcopyright} 2018 by Taylor & Francis Group, LLC.",

year = "2017",

month = jan,

day = "1",

doi = "10.1201/9781315152110",

language = "English (US)",

isbn = "9781498747950",

pages = "3619--3626",

booktitle = "Kucers the Use of Antibiotics",

publisher = "CRC Press",

}

TY - CHAP

T1 - Letermovir

AU - Aitken, Samuel L.

AU - Saunders, Rob

AU - Chemaly, Roy F.

AU - Ehninger, Gerhard

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Letermovir is the first representative of the nonnucleoside 3,4 dihydro-quinazoline class of human cytomegalovirus (HCMV) viral terminase complex inhibitors (Verghese and Schleiss, 2013). Originally developed by Bayer AG (Wuppertal, Germany), with further preclinical and clinical development through phase II by AiCuris GmbH & Co. KG (Wuppertal, Germany), letermovir is now under development by Merck & Co. (Kenilworth, NJ, USA). Letermovir is now in phase III development for the prevention of HCMV infection in allogeneic hematopoietic cell transplant (HCT) recipients (clinical trials NCT02137772). Owing to its development history, letermovir is variously known as BAY 73-6327, AIC246, and MK-8228. The chemical name of letermovir is 2-((4S)-8-fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)- 3-(2-methoxy-5)-trifluoromethyl)phenyl)-4H-quinazolin- 4-yl)acetic acid (PubChem Open Chemistry Database, 2016), the molecular formula is C29H28F4N4 O4, and its molecular weight is 572.55 g/mol. The chemical structure is shown in Figure 220.1.

AB - Letermovir is the first representative of the nonnucleoside 3,4 dihydro-quinazoline class of human cytomegalovirus (HCMV) viral terminase complex inhibitors (Verghese and Schleiss, 2013). Originally developed by Bayer AG (Wuppertal, Germany), with further preclinical and clinical development through phase II by AiCuris GmbH & Co. KG (Wuppertal, Germany), letermovir is now under development by Merck & Co. (Kenilworth, NJ, USA). Letermovir is now in phase III development for the prevention of HCMV infection in allogeneic hematopoietic cell transplant (HCT) recipients (clinical trials NCT02137772). Owing to its development history, letermovir is variously known as BAY 73-6327, AIC246, and MK-8228. The chemical name of letermovir is 2-((4S)-8-fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)- 3-(2-methoxy-5)-trifluoromethyl)phenyl)-4H-quinazolin- 4-yl)acetic acid (PubChem Open Chemistry Database, 2016), the molecular formula is C29H28F4N4 O4, and its molecular weight is 572.55 g/mol. The chemical structure is shown in Figure 220.1.

UR - http://www.scopus.com/inward/record.url?scp=85056681278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056681278&partnerID=8YFLogxK

U2 - 10.1201/9781315152110

DO - 10.1201/9781315152110

M3 - Chapter

AN - SCOPUS:85056681278

SN - 9781498747950

SP - 3619

EP - 3626

BT - Kucers the Use of Antibiotics

PB - CRC Press

ER -

Letermovir

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this